69
Blood brain barrier The CNS blood brain barrier is created by tight  junctions between endothelial cells and a basement membrane supported by astrocytic foot processes; this presents a formidable barrier to drug penetration. Lipid soluble agents or drugs with specific transport mechanisms can penetrate rapidly.

Distribution Scop

Embed Size (px)

Citation preview

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 1/69

Blood brain barrier

� The CNS blood brain barrier is created by tight

 junctions between endothelial cells and a

basement membrane supported by astrocytic

foot processes; this presents a formidable

barrier to drug penetration. Lipid soluble

agents or drugs with specific transport

mechanisms can penetrate rapidly.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 2/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 3/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 4/69

Approaches to BBB

� Use of permeation enhancers such as

dimethyl sulphoxide (DMSO)

� Osmotic disruption of the BBB by infusinginternal carotid artery with mannitol.

� Use of dihydropyridine redox system as drug

carriers to the brain.(Prodrug for polar drugs)

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 5/69

Brain Cerebrospinal fluid barrier

� CSF is formed mainly by the choroid plexus of 

the lateral, third and fourth ventricles

� It is similar in composition to the ECF of the

brain.

� Characteristics' similar to that of BBB

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 6/69

� The capillary endothelium that lines the

choroid plexus have open junctions or gapsand drugs can flow freely into the extracellular

space between the capillary walls and the

choroidal cells.

� Choroidal cells are joined to each other bytight junctions forming blood-CSF barrier

which has permeability similar to BBB

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 7/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 8/69

� For Any given drug conc. In brain higher than

in CSF, because bulk flow of CSF continuously

removes drug.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 9/69

Blood placental barrier

� Number of tissue layers

� Mean thickness of the barrier 25 microns in

early pregnancy, 2 microns in full term� < 1000 Daltons MW & moderately high lipid

soluble drugs cross the barrier by simple

diffusion quite rapidly.

� Not as effective a barrier as BBB

� Nutrients carrier mediated process

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 10/69

Drugs in the mother's blood can cross the placental

membrane into blood vessels in the villi and pass

through the umbilical cord to the fetus

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 11/69

PERFUSION OR PERMEATION RATE

LIMITED

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 12/69

� Perfusion rate: defined as the vol. of 

blood that flows per unit time per unitvol. of tissue, ml/min/ml

� Highly perfused :lungs,kidneys,liver,heart

,brain

� Moderately perfused: muscles, skin

� Poorly perfused: bones,fat(adipose

tissue)

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 13/69

� Kt=perfusion rate/Kt/b

� Kt/b=tissue/blood partition coefficent of drug

� Kt=Distribution rate constant� Tissue Distribution half life=0.693/Kt=

0.693/Kt/b

� Eg thiopental: lipophilic, high Kt/b towards brain still higher for

adipose tissue. Brain highly perfused organ, iv inj. Rapid onset of 

action, adipose tissue poorly perfused, vol 5 times that of brain.

Rapid termination of action due to tissue redistribution.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 14/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 15/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 16/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 17/69

ORGAN TISSUE AND PERFUSION

RA

TE

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 18/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 19/69

Miscellaneous factors

� Age

� Total body water: much greater in infants

� Fat contents: higher in infants& elderly� Skeletal muscles: lesser in infants & elderly

� Organ composition: BBB poorly developed in

infants , mylein content high,>penetration of drugs in brain

� Plasma protein content : low albumin in

infants and elderly

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 20/69

� Pregnancy : Vol. available fordistribution of drugs is high.

� Plasma and ECF vol. also increase but

there is fall in albumin content.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 21/69

Miscellaneous factors

� Obesity: high adipose tissue

� Diet� Disease States: altered albumin and other

drug-binding protein conc.

� Altered organ/tissue perfusion.� Altered pH

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 22/69

Drugs appear to distribute in the body as if it werea single compartment. The magnitude of the drug¶s

distribution is given by the apparent volume of distribution (Vd). Vd bears no direct relation shipwith real vol of distribution.

Amount of drug in bodyConcentration in Plasma

Vd =

VOLUME OF DISTRIBUTIONVOLUME OF DISTRIBUTION

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 23/69

Volume of Distribution

Volume into which a drug appears todistribute with a concentration equal to its

 plasma concentration

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 24/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 25/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 26/69

Determination of Physio. Vol.

� Plasma vol:Tracers or markers ; subs of high mol

wt totally bound to plasma ALBUMIN Evans

blue, Indocyanine green, I-131

� ECF: easily penetrate capillary membrane &

rapidly distribute through ECF but donot cross

cell memb.:mannitol,inulin,ions(Na+,Cl-

,sulphate)

� TBW: subs that distribute equally in all water

compts. Heavy water, tritiated water,antipyrine

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 27/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 28/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 29/69

Vd is useful in determining an appropriate dose toobtain a particular plasma level, therapeuticlevels are measured and referenced to plasmalevels.

 A large Vd has an important influence on the half-life of a drug because elimination usuallydepends on the amount of free drug deliveredto the liver or kidney, with a large volume of distribution much/most of a drug will beextravascular or protein bound and not readilyavailable to excretory organs.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 30/69

CONCLUSION:

FACTORS THAT PRODUCE ALTERATION IN

BINDING OF DRUG TO BLOOD COMPONENTS:

INCREASES Vd

FACTORS THAT INFLUENCE DRUG BINDING TO

EXTRAVASCULAR COMPONENTS: DECREASES

Vd

OTHER FACTORS:TISSUEPERFUSION,PERMEATION,IONISATION,

DISEASE STATE ETC.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 31/69

PROTEIN BINDING

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 32/69

� Intracellular binding: when drug is bound to a

cell protein which may be the drug receptor, if 

so, binding elicits a pharmacological

response.receptors:primary receptors

� Extracellular binding: when drug is bound to a

extracellular protein but the binding doesnot

elicits a pharmacologicalresponse.receptors:secondary,silent receptors

� Binding reversible, suggests weak

bonds(hydrogen, vanderwalls)

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 33/69

PROTEIN ± DRUG BINDING

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 34/69

Plasma protein binding

� Entry into systemic circulation, first thing

which can interact with drug: blood

components, like plasma proteins, blood cells,

Hb

� Binding to plasma protein reversible

� Mostly bound to albumin

� HAS: MW 65000, abundant(59% of total

plasma)

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 35/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 36/69

Binding of drugs to HSA

� Warfarin site: NSAIDs,bilirubin,phenytoin,

sodium valproate

� Diazepam binding site: benzodiazepines,ketoprofen, ibuprofen, trytophan

� Site III and IV : very few drugs bind.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 37/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 38/69

� Primary site

� Secondary site:

� eg. Dicoumarol primary site1, secondary site 2� Drugs compete for site

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 39/69

Tissue binding of drugs

� 40% of body wt is tissue. 100 times that of HSA.

� it increases Vd

� Results in localisation of drug at specific site in

body, some drugs bind irreversibly to tissues

eg. oxidation pdts of PCM,

phenacetin,chloroform etc. bind covalently to

hepatic tissues.

� Extensive tissue binding suggest tissue can act

as a storage site for drugs.

� liver>kidney>lung>muscles

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 40/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 41/69

DETERMINATION OF PROTEIN BINDING

� Indirect techniques: based on separation of 

bound form from the free micromolecule.

:equilibrium dialysis, dynamic dialysis, ultra

filtration, gel filtration, ultracentrifugation

� Direct techniques: Do not require separationof bound form of drug from the free

micromolecule: spectroscopy, fluorimetry, ion

selective electrodes

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 42/69

FACTORS AFFECTING PROTEIN BINDING

� Drug related factors

� Protein-tissue related factors

� Drug interactions

� Patient related factors

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 43/69

Drug related factors

� Conc. of drug in the body: HSA 

no saturation, lidocaine can saturate AAG

� Drug-protein tissue affinity� Lidocaine greater affinity for AAG than has ,

digoxin greater affinity for protein of cardiacmuscles than skeletal muscles

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 44/69

Physicochemical characteristics of the drug

� Lipophilicity and larger binding, eg.slowabsorption of cloxacillin in comparison to

ampicillin after im inj.

� Anionic or acidic drugs bind more to HAS

� Cationic or basic drugs bind more to AAG

� Neutral unionized drugs bind more tolipoproteins

� Stereo selective binding eg.

Chloroquin,propranolol,ibuprofen

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 45/69

Protein-tissue related factors

� Physicochemical properties of 

protein/Binding component

� Lipoproteins & adipose tissue bind lipophilic drugs

by dissolving them in the lipid core.

� Conc. of protein/Binding component

� Number of binding sites on proteins� AAG limited binding sites, albumin large no.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 46/69

DRUG INTERACTIONS

� Competition between Drugs for binding sites� Drug -drug interaction for the common

binding site is called displacement reaction.

� Displaced drug---displacer� Eg. Warfarin displace by phenylbutazone

phenylbutazone---HAS

� Free warfain may cause hemorrhagicreactionwhich may be lethal.

� Unexpected rise in free drug conc. ---toxicity

or enhanced clinical response

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 47/69

� Clinically significant interaction occurs when:

� Displaced drug:

� is more than 95% bound� Has a small Vd (less than 0.15L/kg)

� Shows rapid onset of therapeutic or adverse

effects� Has a narrow therapeutic index

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 48/69

� Displacer drug:

� has higher degree of affinity for protein

competes for same binding site

� Drug/ protein conc. ratio is high(above 0.10)

� Showa a rapid and large increase in plasma

drug conc.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 49/69

� 95% bound drug, displacement of 5% bound

drug results in 100% increse in free drug conc.

� Small Vd: remains in blood ---toxicity

� Large Vd; redistributes into large vol of body

fluids----insignificant clinical effects

� increase in free drug conc.---more available for

elimination

� If drug easily metabolisable or excretable

displacement results in in elimination half 

life

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 50/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 51/69

� Competition between drugs and normal body

constituents

� Free fatty acids are known to interact with a no. of 

drugs that bind primarily to HSA.

� Free fatty acid in fasting, pathological conditions,

pcologically induced conditions(after caffeine,heparin admin.)

� Influence binding of several benzodiazepines,

prpranolol, warfarin� Bilirubin binding to HSA-acidic drugs--free bilirubin

not conjugatedneonates---kernicterus.

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 52/69

Patient related factors

� Age

� Inter subject variation� Disease state

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 53/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 54/69

Conclusion

� All factors that affect protein bindinginfluence:

� 1. Pharmacokinetics---in plasma-protein

drug binding--- in unbound drug---tissue

redistribution/clearanceenhnace

biotransformation, excretion

� 2. Pharmacodynamics---- in conc. of free or

unbound drug results in intensity of action

(therapeutic/toxic)

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 55/69

Significance of protein tissue binding of drugs

�A

bsorption� Displacement interactions & toxicity

� Systemic solubility of drug

� Distribution

� Tissue binding

� Elimination

� Diagnosis(thyroid gland iodine compds)

� Therapy and drug targeting

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 56/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 57/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 58/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 59/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 60/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 61/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 62/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 63/69

KINETICS OF PROTEIN BINDING

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 64/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 65/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 66/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 67/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 68/69

8/6/2019 Distribution Scop

http://slidepdf.com/reader/full/distribution-scop 69/69